An intravenous antibody treatment for specified forms of multiple sclerosis, distinct from the subcutaneous combination product.
Profile scope: Ocrelizumab intravenous. Confirm the exact product and route; formulations and combination products are not interchangeable.
Possible side effects
Limb discomfort or swelling may occur.
Serious risks and warning signs
Serious infection, new neurological changes, severe or persistent headache, or bloody or persistent diarrhea require prompt assessment. NIH describes concern about certain cancers. Infusion-reaction precautions are important.
A question for your healthcare team
Which infection screening and infusion monitoring apply, and which delayed symptoms need an urgent call?
What to do with this information
Discuss persistent or troubling symptoms with your prescriber or pharmacist. For severe breathing difficulty, collapse, a seizure, or inability to wake someone, seek emergency help. Read the linked medicine information for drug-specific instructions, including situations requiring immediate action. For routine treatment changes, consult your prescriber rather than changing your dose on your own. Follow the urgent action instructions above and in the linked medicine information.
Sources
Sources checked November 20, 2026. An original AI-assisted educational summary, not a complete adverse-effect or interaction list. This profile is part of the broader library expansion, not the original prescription-use ranking. Inclusion does not confirm current product availability or mean that risks outweigh benefits. This page has not been independently reviewed by a clinician.